Limited Upside To JBM (2161 HK)'s Spin-Off
On the 17th July 2026 , JBM (Healthcare) (2161 HK), a consumer healthcare company, announced the spin-off of 100%-held JPJ, the group’s branded PCM products and Chinese medicine clinic services.
Listing is slated for the HKEx, market conditions permitting. An application proof has been lodged. JBM intends to hold at least 50% of JPJ post listing.
My calcs suggest JBM is fairly valued here - before assigning any holdco discount post spin-off. FWIW, JBM was itself spun-off from Jacobson Pharma (2633 HK) in February 2021.
JBM (Healthcare) (2161 HK) is illiquid - look away now if this is not your bag.
The Trade:
JBM is hedging on JPJ’s “heritage brand + clinic synergy” offsetting JBM’s and (likely) JPJ’s illiquidity.
My view is that the key beneficiary from this latest spin-off will be JBM’s chairman and controlling shareholder, as JBM in-species its JPJ holding in the future. If beneficial ...
Keep reading with a 7-day free trial
Subscribe to Hong Kong/China M&A/Events to keep reading this post and get 7 days of free access to the full post archives.